ArticleEuropean journal of haematology2023

High risk of infection in 'real-world' patients receiving ibrutinib, idelalisib or venetoclax for mature B-cell leukaemia/lymphoma.

Amanda Tey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.